Pre‐RAI Monocyte‐to‐Lymphocyte Ratio Predicts Early and Higher Recurrence Risk in Intermediate‐Risk Differentiated Thyroid Carcinoma (DTC), While PNI and NRI Show No Prognostic Value
Main finding · Prediction of recurrence by pre-RAI MLRResult — go to the resultOdds ratio 4.94Authors' conclusion
Pre-RAI MLR may serve as a simple marker to refine recurrence risk stratification and personalize follow-up in intermediate-risk DTC.
Study context
- Population
- Patients with intermediate-risk DTC (ATA), excellent or indeterminate response 12 months after initial treatment, ≥3 years of follow-up after thyroidectomymedian follow-up 91 months
- Participants
- 282 patients
- Exposure
- High vs low pre-RAI monocyte-to-lymphocyte ratio (MLR)
- Outcome
- Recurrence
Methodological detailsconsecutive patients, single-centre
- Consecutive patients
- Single-centre
Main finding
Prediction of recurrence by pre-RAI MLR
Odds ratio
4.94
P < 0.001
As reported in the abstract
Observational data: associations, not effects.
Further findings
Other independent predictors of recurrence
- Tumor size, vascular invasion and lymph node metastases independently associated with recurrence
Nutritional indices (PNI, NRI)
- Nutritional indices showed no prognostic value
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Pre‐RAI Monocyte‐to‐Lymphocyte Ratio Predicts Early and Higher Recurrence Risk in Intermediate‐Risk DTC, While PNI and NRI Show No Prognostic Value. Clin Endocrinol (Oxf). Published 23 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →